AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen

AbbVie’s latest upbeat read on its Q2 numbers included a sour note that is likely to put another one of Biogen’s top pipeline projects under a cloud.

The pharma giant said today that they shut down a Phase II trial for the anti-tau drug ABBV-8E12 after investigators determined that the data indicated it was useless to push ahead on a neurodegenerative study for progressive supranuclear palsy.